The American Diabetes Association and its journal Diabetes, has published "Altered Function of Antigen-Presenting Cells in Type 1 Diabetes: A Challenge for Antigen-Specific Immunotherapy?" by CCTI Principal Investigator, Dr. Remi Creusot and his lab researchers, Nato Teteloshvili and Jorge Postigo-Fernandez.
In this comprehensive review, Dr Creusot's lab examines different aspects of anitgen-presenting cells (APCs) function that are pertinent to tolerance induction and summarize how they are altered in the context of Type 1 Diabetes (T1D). They attempt to reconcile 25 years of studies on why T1D arises from a failure to maintain tolerance to specific β-cell antigens, highlighting genetic, phenotypic, and functional features that are common or distinct between humans and animal models. Finally, they discuss the implications of these defects and the challenges they might pose for the use of antigen-specific immunotherapy to treat T1D. For the online version of the review in the August, 2018 issue of Diabetes, please click here.